' No Surprises ' as Ozanimod Holds up in RMS Extension Trial ' No Surprises ' as Ozanimod Holds up in RMS Extension Trial

Nearly 70% of patients with relapsing forms of MS were relapse-free at 5 years, but hematologists disagree over where the drug fits in the treatment plan.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Source Type: news